Bhringraj for Hair Growth: Examining the Claim

Bhringraj — Eclipta prostrata, still labelled Eclipta alba almost everywhere — is called kesharaja in Sanskrit, "king of hair". Of the several dozen herbs this site has examined for a hair claim, this is the most interesting case, and it is interesting for an unusual reason: the preclinical evidence is not vague. It is not an antioxidant assay stretched into a hair argument. Rodent studies applied the extract to skin, measured how many days hair took to reappear, and ran minoxidil as the comparator — the actual drug, in the actual outcome. That is a real experiment asking close to the right question.

And there is still no adequate controlled human trial. Not a failed one. An absent one. This page reports the animal work accurately, because it deserves accuracy, then sets out exactly what a human trial would have to measure, names the instruments that already exist for measuring it, and shows that a comparable herb — rosemary — was put through precisely that trial. The tools are not missing. They were simply never pointed at this plant.

Table of Contents

  1. The Short Answer, Ranked
  2. What the Rodent Studies Actually Found
  3. What a Shaved Mouse Does and Does Not Represent
  4. Why "Better Than Minoxidil" Is Weaker Than It Sounds
  5. The Route and Vehicle Problem
  6. What an Adequate Human Trial Would Have to Do
  7. The Herb That Did Get Trialled
  8. Greying, Staining and a Backwards Argument
  9. What the Oil Plausibly Does Do
  10. Evidence Ledger
  11. Key Research Papers
  12. Connections

The Short Answer, Ranked

Ranked by how well established each statement is — deliberately not in the order the marketing puts them:

  1. Best established: the plant is chemically well characterised. Wedelolactone and demethylwedelolactone — coumestans — plus ecliptasaponins and eclalbasaponins, luteolin, apigenin, sterols and thiophenes. This is not in dispute.
  2. Well established: topical use of the traditional oil has a long record and no notable toxicity signal. Safety-by-usage-history is the strongest practical claim available here.
  3. Genuine preclinical finding: topical Eclipta alba extract shortened the time to hair-growth initiation and completion in shaved rodents and in a testosterone-induced alopecia model, compared with a minoxidil-treated control group.
  4. Plausible mechanism: a telogen-to-anagen shift, which is roughly what minoxidil does. Coherent, and observed only in animals and cells.
  5. Absent: any randomised, controlled, adequately powered human trial of bhringraj alone for any form of hair loss. Absent, not negative — nobody has run and failed this experiment. Nobody has run it.
  6. Not supported by any evidence tier: that bhringraj reverses grey hair biologically. The plant does deposit black pigment, which is a dye effect and washes out.

Notice the shape of that list. The two firmest items are a chemistry fact and a safety fact. The item people buy the oil for is fifth.

What the Rodent Studies Actually Found

Two pieces of work carry essentially the whole claim, and both are real published experiments rather than the citation-loop of wellness articles that usually stands behind a herbal hair claim.

The rat study. Roy, Thakur and Dixit reported hair-growth promoting activity of Eclipta alba in male albino rats in Archives of Dermatological Research in 2008. Petroleum-ether and ethanol extracts were applied to shaved dorsal skin; the endpoints were time to complete regrowth and the proportion of follicles in the growth (anagen) phase on histology, against a vehicle control and minoxidil as the positive control. Both extracts shortened regrowth time and raised the anagen:telogen ratio.

The mouse study. Datta and colleagues reported an Eclipta alba extract with potential for hair-growth promoting activity in the Journal of Ethnopharmacology in 2009. This is the more interesting of the two because it used two models, not one: ordinary shaved mice, and mice given testosterone to induce an androgen-driven suppression of hair growth. In both, the extract reduced the time to hair-growth initiation and the time to completion relative to the minoxidil-treated group.

A deliberate omission. This page does not quote the day counts or the percentage improvements from either paper. They are widely reproduced online, they differ between retellings, and a specific figure stated here would be a figure taken on trust rather than read off the record. Per this site's standing rule: where the exact number cannot be verified, the finding is described and the reader is given a link to check it. The direction of both results is not in doubt.

Supporting cell work exists too — extracts and fractions reported to increase dermal papilla cell proliferation and to alter growth-factor and Wnt-pathway signalling in follicle-derived cells. A live search for Eclipta and dermal papilla cells will show the current state of it. Cell-culture proliferation is the weakest tier in this whole ladder and is listed for completeness, not as support.

What a Shaved Mouse Does and Does Not Represent

The depilation-induced regrowth model is a good model of one thing and a poor model of the thing readers have.

Rodent follicles cycle in synchronised waves. On a mouse or rat back, neighbouring follicles enter and leave anagen together, and shaving or plucking itself triggers a coordinated new anagen. This is well documented — the standard reference work on classifying murine hair-cycle stages exists precisely because the phases are so cleanly synchronised that they can be staged histologically; see the guide to accurate classification of murine hair follicles in distinct hair cycle stages, published in the Journal of Investigative Dermatology in 2001. The consequence is that the readout is timing, and timing is easy to nudge. Massage, mild irritation, occlusion and several inert oils can all move it measurably.

Human scalp follicles cycle independently. Each follicle runs its own clock, which is why humans shed roughly a hundred hairs a day rather than moulting. There is no synchronised wave to accelerate, so "time to regrowth after shaving" is not an outcome that exists on a human head.

The dominant human condition is miniaturisation, not delay. Androgenetic alopecia is a progressive shortening of anagen and shrinking of the follicle under dihydrotestosterone signalling, ending in a fine, short, unpigmented hair. Nothing about "days to regrowth in a shaved rat" tests that. The testosterone-induced mouse model in the 2009 study is a partial answer to this objection — it at least introduces androgen — but androgen-suppressed murine regrowth is still not follicular miniaturisation in a genetically predisposed human scalp.

None of this means the rodent result is fake. It means the model's positive predictive value for human scalp outcomes is low, which is a claim about the history of the field rather than about this plant: the hair-loss literature contains a long list of compounds that regrew rodent fur and did nothing on human heads. That history is the reason human trials are required, and it is the reason a mouse result cannot be reported as "clinically proven".

Why "Better Than Minoxidil" Is Weaker Than It Sounds

The single most repeated line in bhringraj marketing is that it beat minoxidil. Taken literally, that is a fair summary of what the 2009 mouse experiment reported. Taken as a claim about people, it inverts what a positive control is for.

The honest version of the marketing line is: in a shaved-mouse assay, an ethanolic extract moved the timing endpoint further than 2% minoxidil did. That is genuinely worth a human trial. It is not a human result.

The Route and Vehicle Problem

This is the gap that almost every article skips, and it is decisive. The preparation studied is not the preparation sold.

One honest point in the oil's favour. Of the two extracts in the 2008 rat study, petroleum ether is a non-polar solvent, so its active fraction is broadly the fat-soluble one — the same fraction an oil infusion would capture. That is the one place where the solvent mismatch argument cuts slightly towards the traditional preparation rather than against it. It is worth saying because it is true, and because pages that only ever list objections are as unreliable as pages that only list benefits. It remains a chemical plausibility argument about a rodent result, not evidence in a person.

What an Adequate Human Trial Would Have to Do

The strongest honest thing that can be said about a herb with no trial is to specify the trial. It removes the excuse that traditional remedies cannot be tested, because every instrument below is standard equipment in dermatology research and is used routinely on drugs and on other botanicals.

Design. Randomised, double-blind, at least two arms — standardised bhringraj preparation versus identical vehicle — and ideally a third arm of 5% topical minoxidil for context. Vehicle control is not optional here: the carrier oil and the massage both plausibly do something, so a trial without a vehicle arm cannot attribute anything to the plant.

Population and duration. A defined diagnosis, staged — androgenetic alopecia by Hamilton-Norwood or Ludwig grade, or telogen effluvium with a positive wash test — not "people who feel their hair is thinning". Minimum 24 weeks, preferably 48, because the hair cycle is measured in months and because minoxidil's own early shedding phase can make 8-week data point the wrong way.

Primary endpoint. Target-area hair count: a tattooed or otherwise permanently marked 1 cm² scalp region, photographed under fixed magnification and lighting, counted blind. Terminal versus non-terminal hair counts reported separately, because a shift from fine to thick hair is the clinically meaningful change in pattern loss.

Validated instruments that already exist for this.

  1. Phototrichogram and TrichoScan — epiluminescence microscopy with digital image analysis, giving hair density, diameter and the anagen:telogen ratio from the same site over time. The method was described in the European Journal of Dermatology in 2001 and has been used in botanical trials since.
  2. Trichoscopy — dermoscopy of the scalp, which quantifies hair-diameter diversity, the specific marker of miniaturisation.
  3. Standardised global photography assessed by a blinded expert panel on a 7-point scale — the regulatory workhorse endpoint for hair-growth drugs.
  4. Wash test and modified hair-pull test for shedding, which is what patients actually notice.
  5. Patient-reported outcomes on a validated hair-specific quality-of-life instrument.
  6. Product characterisation — the intervention assayed for wedelolactone content, so a positive result could be reproduced by someone else.

Every one of those is in routine use; a live search of randomised alopecia trials using target-area hair counts and trichoscopy returns a large literature. None of it has been applied to Eclipta prostrata. The absence is not a limitation of traditional medicine. It is an unspent research opportunity on the one herbal hair claim with the most specific preclinical rationale behind it.

The Herb That Did Get Trialled

The clearest proof that a herbal hair claim can be tested is that one was. Panahi and colleagues randomised men with androgenetic alopecia to rosemary oil or 2% minoxidil for six months and reported the comparison in Skinmed in 2015, with hair counts at three and six months. Both groups improved and the difference between them was not significant.

Read that carefully in both directions, because it is routinely oversold:

So the honest ranking is that rosemary sits one full tier above bhringraj on human evidence, and that tier is still not "proven". Our rosemary and hair loss page works through that trial and its limits in detail. If someone wants a topical botanical with any controlled human hair data, that is where it is — not here.

Greying, Staining and a Backwards Argument

Bhringraj's second claim is that it darkens greying hair, and it is here that the plant's most conspicuous physical property misleads everybody. Crushed Eclipta sap oxidises to a deep blue-black. Vietnamese and Indian names for the plant mean "ink grass" and "soot from the cooking pot". It stains skin, cloth, paper and hair.

That is a dye. It deposits colour on the outside of a hair shaft and it washes out. It is not repigmentation, for two reasons that hold regardless of what is applied:

Do not run the tyrosinase argument

There is a specific error circulating in botanical hair writing, and it needs naming here because bhringraj is at risk of inheriting it. Tyrosinase-inhibition data is sometimes offered as evidence that a plant helps grey hair. The inference runs backwards. Tyrosinase is the rate-limiting enzyme in melanin synthesis, so tyrosinase inhibitors reduce pigment production — which is why they are the active principle of skin-lightening products. Citing an extract's tyrosinase inhibition in support of restoring hair colour argues for the opposite of the intended conclusion.

Our curry leaf hair and skin page documents this error in detail for that plant, and the same correction applies to any Eclipta source that reaches for tyrosinase assays. Where bhringraj's greying claim is defended by antioxidant or enzyme-assay data rather than by the plant's ink, it is being defended by the wrong argument. Where it is defended by the ink, it is a dye claim and should be labelled as one.

What is worth doing instead: premature greying with other symptoms has correctable causes worth ruling out — vitamin B12 deficiency, low iron stores, copper status since copper is tyrosinase's required cofactor, and thyroid disease. Those are cheap blood tests. Early greying with nothing else going on is usually genetic, and there is no treatment for that beyond dye or acceptance. Saying so is more useful than selling hope.

What the Oil Plausibly Does Do

Users are not imagining an improvement. There are three unglamorous explanations that fit the observation better than follicular stimulation does.

  1. The carrier oil reduces breakage. Coconut oil's effect on hair-shaft protein loss was measured against mineral and sunflower oils in the Journal of Cosmetic Science in 2003, with coconut oil performing best. Hair that snaps less looks thicker and longer. This is an effect of the vehicle, not of the Eclipta, and it is one of the better-supported things in the whole cosmetic literature.
  2. Massage is a variable in its own right. Standardised scalp massage was reported to increase hair thickness by inducing stretching forces on dermal papilla cells in Eplasty in 2016 — a small, uncontrolled study, so treat it as a hypothesis. But it means the ritual of applying an oil is not an inert background condition, and it is another reason a vehicle-controlled trial is mandatory.
  3. Hair loss fluctuates, and people start treatments at their worst. Telogen effluvium after illness, crash dieting, childbirth or stress typically recovers on its own over six to nine months. Anyone who starts an oil at the peak of a shed will see improvement they would have seen anyway. This is regression to the mean, and it is the single largest source of sincere testimonials in the hair-product market.

Add to that a genuinely healthier scalp surface if flaking and itch settle — though if the scalp is scaling, that may be seborrheic dermatitis, which has actual treatments.

Evidence Ledger

Claim, best available tier, and verdict — distinguishing absent (never tested) from negative (tested and failed), because collapsing the two flatters the untested claim and unfairly damns the tested one.

Key Research Papers

Why every link is a search. Each link below runs a PubMed search rather than opening a numeric record. A mistyped identifier silently delivers a different paper, usually one in the same journal issue, and that failure is invisible to the reader. A search always resolves and lets you confirm the title, journal and year yourself. Metadata is given as plain text for exactly that reason.

  1. Roy RK, Thakur M, Dixit VK. Hair growth promoting activity of Eclipta alba in male albino rats. Archives of Dermatological Research, 2008. Animal. Petroleum-ether and ethanol extracts, rat dorsal skin, minoxidil positive control.
  2. Datta K, Singh AT, Mukherjee A, et al. Eclipta alba extract with potential for hair growth promoting activity. Journal of Ethnopharmacology, 2009. Animal. Shaved-mouse and testosterone-induced alopecia models; the source of the "faster than minoxidil" line.
  3. Müller-Röver S, Handjiski B, van der Veen C, et al. A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. Journal of Investigative Dermatology, 2001. Why rodent hair cycling is synchronised, and why timing endpoints are easy to move.
  4. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology, 2004. Needed to interpret the comparator, including the sulfotransferase activation step.
  5. Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A. Rosemary oil versus minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed, 2015. Human, randomised, no placebo arm. The benchmark bhringraj has not met.
  6. Nishimura EK, Granter SR, Fisher DE. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science, 2005. Why repigmentation claims fail at the first hurdle.
  7. Wood JM, Decker H, Hartmann H, et al. Senile hair graying: hydrogen peroxide-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB Journal, 2009. The oxidative component the antioxidant argument appeals to — and its limits.
  8. Arck PC, Overall R, Spatz K, et al. Towards a "free radical theory of graying": melanocyte apoptosis in the aging human hair follicle. FASEB Journal, 2006.
  9. Rele AS, Mohile RB. Effect of mineral oil, sunflower oil, and coconut oil on prevention of hair damage. Journal of Cosmetic Science, 2003. The carrier-oil effect that a bhringraj oil trial would have to control for.
  10. Koyama T, Kobayashi K, Hama T, et al. Standardized scalp massage results in increased hair thickness by inducing stretching forces to dermal papilla cells in the subcutaneous tissue. Eplasty, 2016. Small, uncontrolled. Why the massage is a variable.
  11. Hoffmann R. TrichoScan: combining epiluminescence microscopy with digital image analysis for the measurement of hair growth in vivo. European Journal of Dermatology, 2001. One of the instruments that exists and was never pointed at this plant.

Live PubMed Searches

  1. Eclipta and hair — search both binomials; a single-name search misses half the literature.
  2. Eclipta alopecia clinical trial — the search that should return a trial and does not.
  3. Eclipta and dermal papilla cells
  4. Alopecia trials using target-area hair counts and trichoscopy — what an adequate trial looks like.
  5. Greying and melanocyte stem-cell depletion
  6. Premature greying, B12, ferritin and thyroid — the correctable causes.
  7. Telogen effluvium and spontaneous recovery — the reason testimonials are unreliable.
  8. Tyrosinase inhibitors and skin lightening — confirming which direction that argument runs.
  9. Herbal hair oils in randomised trials — multi-herb products, which cannot attribute an effect to one ingredient.

Connections

This page is educational and is not medical advice. Bhringraj is not a proven treatment for hair loss or grey hair: the evidence is traditional use plus rodent studies, and no adequate controlled human trial exists. If hair is shedding noticeably or greyed unusually early, ask a clinician about ferritin, thyroid function and B12 before spending money on oils, and see a dermatologist about pattern loss while the follicles are still there to save.

Back to Table of Contents